vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
WEST BANCORPORATION INC is the larger business by last-quarter revenue ($26.9M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -0.8%, a 40.1% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs -25.7%). WEST BANCORPORATION INC produced more free cash flow last quarter ($12.4M vs $-15.8M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
CTMX vs WTBA — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $26.9M |
| Net Profit | $-154.0K | $10.6M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 50.0% |
| Net Margin | -0.8% | 39.2% |
| Revenue YoY | -25.7% | 16.6% |
| Net Profit YoY | 97.6% | 34.8% |
| EPS (diluted) | — | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | — | $24.2M | ||
| Q3 25 | — | $25.0M | ||
| Q2 25 | $18.7M | $23.8M | ||
| Q1 25 | $50.9M | $23.1M | ||
| Q4 24 | $38.1M | $20.9M | ||
| Q3 24 | $33.4M | $20.3M | ||
| Q2 24 | $25.1M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | — | $7.4M | ||
| Q3 25 | — | $9.3M | ||
| Q2 25 | $-154.0K | $8.0M | ||
| Q1 25 | $23.5M | $7.8M | ||
| Q4 24 | $18.9M | $7.1M | ||
| Q3 24 | $5.7M | $6.0M | ||
| Q2 24 | $-6.5M | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | — | 39.6% | ||
| Q3 25 | — | 45.8% | ||
| Q2 25 | -6.9% | 43.4% | ||
| Q1 25 | 44.4% | 43.4% | ||
| Q4 24 | 46.4% | 30.9% | ||
| Q3 24 | 12.3% | 36.6% | ||
| Q2 24 | -33.7% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 37.3% | ||
| Q2 25 | -0.8% | 33.5% | ||
| Q1 25 | 46.2% | 34.0% | ||
| Q4 24 | 49.6% | 34.0% | ||
| Q3 24 | 17.2% | 29.3% | ||
| Q2 24 | -26.0% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | — | $0.44 | ||
| Q3 25 | — | $0.55 | ||
| Q2 25 | — | $0.47 | ||
| Q1 25 | — | $0.46 | ||
| Q4 24 | — | $0.41 | ||
| Q3 24 | — | $0.35 | ||
| Q2 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $270.7M |
| Total Assets | $175.1M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | — | $471.1M | ||
| Q3 25 | — | $232.9M | ||
| Q2 25 | $49.0M | $345.2M | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | $243.5M | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | — | $266.0M | ||
| Q3 25 | — | $255.1M | ||
| Q2 25 | $119.9M | $240.9M | ||
| Q1 25 | $25.0M | $237.9M | ||
| Q4 24 | $-456.0K | $227.9M | ||
| Q3 24 | $-23.5M | $235.4M | ||
| Q2 24 | $-31.2M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | — | $4.1B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $175.1M | $4.1B | ||
| Q1 25 | $98.5M | $4.0B | ||
| Q4 24 | $120.5M | $4.0B | ||
| Q3 24 | $139.0M | $4.0B | ||
| Q2 24 | $159.2M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $12.9M |
| Free Cash FlowOCF − Capex | $-15.8M | $12.4M |
| FCF MarginFCF / Revenue | -84.6% | 46.0% |
| Capex IntensityCapex / Revenue | 0.1% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | — | $46.5M | ||
| Q3 25 | — | $11.4M | ||
| Q2 25 | $-15.8M | $13.5M | ||
| Q1 25 | $-21.0M | $9.7M | ||
| Q4 24 | $-19.9M | $39.8M | ||
| Q3 24 | $-20.7M | $12.9M | ||
| Q2 24 | $-19.5M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | — | $43.2M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | $-15.8M | $12.8M | ||
| Q1 25 | $-21.2M | $8.3M | ||
| Q4 24 | $-20.0M | $13.7M | ||
| Q3 24 | $-20.7M | $7.0M | ||
| Q2 24 | $-19.6M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | — | 178.3% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | -84.6% | 53.6% | ||
| Q1 25 | -41.6% | 35.7% | ||
| Q4 24 | -52.5% | 65.6% | ||
| Q3 24 | -62.1% | 34.2% | ||
| Q2 24 | -78.2% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | — | 13.7% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.1% | 3.2% | ||
| Q1 25 | 0.2% | 6.5% | ||
| Q4 24 | 0.2% | 125.3% | ||
| Q3 24 | 0.1% | 29.4% | ||
| Q2 24 | 0.4% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 1.70× | ||
| Q1 25 | -0.89× | 1.24× | ||
| Q4 24 | -1.05× | 5.61× | ||
| Q3 24 | -3.61× | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
WTBA
Segment breakdown not available.
